New education platform focuses on diabetes technology training, data management and remote patient monitoring (RPM)

Gothenburg, Sweden (PR NEWSWIRE) — October 28, 2020 — Glooko AB (“Glooko” or “The Company”) today announced, in partnership with the Diabetes Technology Network (DTN)/ Association of British Clinical Diabetologists (ABCD), a new online medical education programme for clinicians who treat people with diabetes in the UK. The programme will help clinicians keep their knowledge base current on the ever-growing assortment of new diabetes technologies that manufacturers make available to people with diabetes. It was inspired after discussions with the National Health Service England (NHSE), as part of its effort to ensure that all healthcare professionals learn uniformly about technology.

Currently, the number of people diagnosed with diabetes in the UK is estimated to be 3.5 million and expected to rise to 5 million by 2025.1

For people with diabetes and their healthcare providers, managing the myriad technologies like glucose monitors and insulin pumps, and the data volume that accompany these technologies, is a well-established challenge. And while tech-based services like web-based programs, telehealth, mobile apps and remote monitoring are improving users’ accessibility and connectivity, the adoption of these innovations has been slow.2

The Academy™ education programme focuses exclusively on diabetes health tech, and includes an extensive range of online courses for healthcare professionals (HCPs), with the intent to increase knowledge, training and usage of these devices – ultimately improving outcomes. All courses are accessed as video modules through the diasend® diabetes data management app and portal, via the DigiBete Global platform.

The programme is available to all diabetes healthcare professionals in the UK at no cost, and is funded in part via sponsorships from global industry partners like Abbott, AgaMatrix, Dexcom, Insulet, Medtronic and Roche Diabetes Care.

Another goal of the educational platform is to reduce barriers to the adoption of diabetes digital tools. DTN UK/ABCD provides guidance on educational content and ensures that the programme aligns with current and future National Health Service England (NHSE) policy/pathways. Healthcare professionals earn CPD accreditation for completing the programme.

“Academy™ is an important investment that sets a new standard for professional development in the diabetes medical technology industry,” said Russ Johannesson, Chief Executive Officer of Glooko. “In collaboration with the NHSE and DTN UK/ABCD, we’ve developed a new, extensive curriculum that will not only equip HCPs to access training that is relevant to their technology skills development, but it will also build a wider range of their capabilities as we move increasingly towards a remote patient monitoring (RPM) environment.”

The curriculum covers over 95% of the diabetes device manufacturers and their technologies, and HCPs that complete the programme will receive Continuing Professional Development accreditation as well as DTN UK/ABCD certification.

“As diabetes technology becomes increasingly widespread in routine clinical practice, we need to train all levels of our diabetes and wider health workforce in what these technologies are and how to use the large amounts of data they generate,” Professor Pratik Choudhary, Professor / Honorary Consultant in Diabetes and Chair of DTN UK, said. “Use of these technologies has transformed how we deliver care, especially during these challenging times. We firmly believe that the collective efforts that we’re cultivating with world-class digital health companies like Glooko will create more value and positively impact outcomes that matter to people with diabetes.”

Prof. Partha Kar, National Specialty Advisor of Diabetes at NHS England, stated “As Nick Fury once said in The Avengers ‘There was an idea’. It’s been a pleasure to bring together multiple partners across industry, specialists in diabetes care – facilitated by Glooko for this project. As diabetes technologies continually advance and improve, it’s critical that healthcare providers have access to the most exceptional training on the plethora of devices that people with diabetes use on a daily basis. This platform will hopefully go a long way in ensuring education is available uniformly across the NHS – and thereby improving access and outcomes for those living with diabetes.”

Glooko is committed to incorporating newly-developed, online immersive education experiences that complement Glooko’s portfolio of industry-leading diabetes digital health solutions.

The Academy™ programme is part of Glooko’s global mission to improve health outcomes by connecting people with diabetes and their healthcare professionals, enabling telehealth, clinical research and improved collaboration.

Rollout of the programme will begin in November 2020 to coincide with World Diabetes Day.

For more information about Academy™: get.glooko.com/academy.

ABOUT GLOOKO
Glooko is transforming digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration.
The company’s software platforms, Glooko and diasend®, empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice. 2.8 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 26 countries across 15 languages. Learn more at glooko.com.

Sources:
1. Diabetes Facts and Stats: 2015 – Diabetes UK, 2015
2. Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care and Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association Diabetes Care / American Diabetes Association (ADA) – June 8, 2020

Media Contacts:
Glooko Inc: [email protected]

MOUNTAIN VIEW, Calif, Aug 12, 2020 – As Glooko continues its journey to transform digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration, today they announced the addition of Tracy Bahl and Mike Doherty as independent members of the Board of Directors to provide guidance and support to the continued growth of the business.

“We are very excited to welcome Mike and Tracy to Glooko,” says Russ Johannesson, CEO at Glooko. “We are proud of our distinguished and active board of directors and Tracy and Mike will complement them with their extensive experience. From the start, Glooko has been dedicated to making the lives of people with diabetes easier, and I am convinced that the addition of our new members will add tremendous value supporting our rapid growth in telehealth and clinical research, in both existing and new geographies.”

Bahl, with an extensive background in senior leadership roles at healthcare companies such as CVS Health and UnitedHealth Group, brings expertise in health plan growth and operations, revenue cycle management and healthcare services. As Glooko expands its global provider footprint and partners with payers and employers, Bahl will be tapped for his expertise and guidance.

“I’m thrilled about the opportunity to join Glooko as a board member and be part of this exciting journey”, Bahl said. “This company provides a unique value proposition for patients, providers and payers, and I see a huge potential for Glooko’s services in support of remote care and remote patient monitoring. With the COVID-19 pandemic, which has affected us all, we’ve seen the need and value of telehealth has grown immensely. As we head into the new normal, Glooko can really make a difference by enabling collaboration and remote care in healthcare.”

Doherty joins Glooko’s board with an in-depth knowledge and experience in regulatory affairs, pharmaceutical development, data strategy and clinical research, from a distinguished career in global companies such as AstraZeneca, Roche and Foundation Medicine where he held a variety of senior leadership roles. With Glooko’s focus on enabling virtual clinical studies and global expansion into new markets, Doherty’s experience is particularly valuable.

“I am excited to be part of Glooko’s board of directors”, Doherty said. “I see a great potential for Glooko to add value in the field of clinical research and real world data by enabling clinical trials globally. I look forward to contributing to the global expansion of this exciting company as it transitions into its next phase of growth.”

ABOUT GLOOKO

Glooko is transforming digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration.

The company’s software platforms, Glooko® and diasend®, empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place.

Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice.

2.8 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 26 countries across 15 languages. Learn more at glooko.com.

MOUNTAIN VIEW, Calif, July 9, 2020 – Together, with Sanofi’s nearly 100-year heritage in diabetes and Glooko’s leadership in remotely connecting people living with diabetes and health care professionals, the companies will collaborate to provide people with diabetes with a digital health solution* to help manage their disease under the virtual guidance of their care teams.

The Glooko Remote Care Solution enables people with diabetes to upload and share data from their diabetes devices with their care providers, who can remotely review diabetes data on the Glooko software platform. Healthcare providers can then provide medical guidance to the person with diabetes via phone, text, or email, bypassing the need for a clinic visit. It is currently being provided free of charge, as a public service to broaden access to telehealth and remote diabetes care during the COVID-19 pandemic.

“At the onset of the pandemic, we quickly realized that we were in a unique position to make a significant contribution towards keeping the diabetes community safe by enabling telehealth and free remote care,” says Russ Johannesson, CEO at Glooko. “We are thrilled to join forces with Sanofi, who share our focus on improving the lives of people with diabetes. Their extensive experience and broad network will support making remote care accessible for even more clinics and people with diabetes.”

“While the world continues to face many challenges as a result of the pandemic, Sanofi is excited to share the Glooko Remote Care Solution with healthcare providers focused on managing diabetes and their patients,” says Chris Boulton, Head of US Diabetes Marketing at Sanofi. “This collaboration puts patient care at the forefront, especially during this stressful time where there is a need for more seamless virtual care.”

To learn more and sign up for Glooko Free Remote Care, visit glooko.com

*Sanofi is not contributing to nor subsidizing the free offer.

ABOUT GLOOKO
Glooko is transforming digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration.

The company’s software platforms, Glooko® and diasend®, empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place.

Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice.

2.8 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 26 countries across 15 languages. Learn more at glooko.com.

Transformative Healthcare Technology Entrepreneur joins leader in diabetes data management

MOUNTAIN VIEW, Calif., April 9, 2020 — As part of its continued focus on delivering data enabled solutions to improve the lives of people with diabetes, Glooko, the leader in diabetes digital health, data management solutions and remote monitoring solutions, today announced the appointment of Kyle Brown as Chief Technology Officer.

Brown joins Glooko with an extensive executive background in digital health, where he has successfully built several technology companies focused on the shift from clinician-entered proprietary registries to open and inclusive Patient Insight Networks.

“We’re very excited to have Kyle joining our company at this important time in our development. His extensive experience building data-driven healthcare technology businesses, together with his unique background in software development, patient advocacy, and support of clinical research, will be incredibly valuable for Glooko as we continue to grow” said Russ Johannesson, CEO of Glooko.

In his new role with Glooko, Brown will have global responsibility for all technology and engineering efforts
“Glooko’s work enhancing the patient-clinician relationship, especially in these times of accelerating adoption of remote care and telemedicine technologies, is a perfect match with my passion for leveraging the digital content to improve patient care,” Brown said. “I am very excited to be a part of the company’s global expansion to create new ways to better engage people with diabetes”.
Brown comes to Glooko from PatientCrossroads/AltaVoice, which he founded and led for over a decade. The company’s mission was to harness the collective knowledge of patient communities to drive faster treatments while creating a market for patient provided data. As CEO, Brown led the implementation of over 125 patient registry programs collecting data on more than 400 diseases in collaboration with advocacy, academia, government and pharmaceutical companies.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.8 million people with diabetes and are used in 9,000+ clinic locations in 25 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts
For inquiries, please email [email protected].

STATEMENT FROM GLOOKO RE: COVID-19 SERVICE

MOUNTAIN VIEW, Calif., March 19, 2020 — Throughout this challenging time of the COVID-19 pandemic, Glooko, a leading diabetes software company that enables people with diabetes and clinicians to manage care in real-time, is committed to helping ensure the health and well-being of people with diabetes, their caregivers, and their healthcare professionals. Glooko is therefore taking action to serve the global diabetes community by providing a no-charge remote-care solution that provides live patient-to-clinician connectivity.

As many efforts undertaken in our communities are aimed at reducing the chances of being exposed to and spreading COVID-19, that individuals who have chronic conditions like diabetes and contract the virus appear to be at a higher risk for developing complications; as such limiting exposure is critical. For certain appointments, healthcare professionals may determine that the patient and their care team would be best served by a remote review of the patient’s personal diabetes data and a corresponding telehealth consult, reserving in-office visits only for those appointments where a patient’s medical status truly requires in-person treatment.

To minimize the risk to people with diabetes during this time by broadening access to remote medical appointments with healthcare providers, Glooko is offering its secure, privacy-protected remote-care solution at no charge to medical clinics and people with diabetes as a public service until the greatest threat of the pandemic has subsided.

This public service is being made available to medical clinics and people with diabetes in countries where Glooko technology is already provided. Interested medical clinics and people with diabetes can learn more about how to access the Glooko remote-care solution at www.glooko.com.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® by Glooko diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.8 million people with diabetes and are used in 9,000+ clinic locations in 25 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts
For inquiries, please email [email protected].

Accomplished business and operational leaders join leader in diabetes data management

MOUNTAIN VIEW, Calif., February 13, 2020 — As part of its continued global expansion, Glooko, the leader in diabetes digital health and data management solutions, today announced the appointment of Zach Henderson as Chief Commercial Officer and Komathi Stem as Chief Operating Officer. Henderson joins Glooko with extensive executive background at healthcare data and analytics companies leading a range of commercial functions, from alliance management and portfolio strategy to sales, marketing, and revenue generation. Stem comes to Glooko having served in a wide range of leadership roles in the life science industry with a focus on the use of real-world data and digital technologies to transform and accelerate clinical trials.

“We’re pleased to have Komathi and Zach joining us now as we expand our offerings to help the global healthcare ecosystem better understand and manage diabetes and support health care providers managing their patient populations using our data, analytics, and clinical research solutions,” said Russ Johannesson, CEO of Glooko. “The year ahead holds tremendous potential for Glooko and having the depth of business and leadership experience that Zach and Komathi bring will be a major advantage as we look forward to significantly increasing our positive impact in the diabetes community.”

In his new role with Glooko, Henderson will have global responsibility for all commercial efforts, including the company’s work with its key strategic partners and revenue generation initiatives.

“As the leader in diabetes data management, Glooko is integrated with more diabetes and health devices than any other platform in the world, creating an opportunity to provide extensive insights. We have a unique opportunity to improve the lives of those with diabetes by leveraging the global Glooko data platform to advance research and the treatment of patients,” said Henderson. “I’m excited to be joining the Glooko team as it transitions to its next phase of growth.”

Henderson comes to Glooko from LexisNexis Health Care and Elsevier, where he served as vice president of strategy, alliances and data sourcing and was responsible for the creation and development of a strategic alliance program of go-to-market and enablement partners, the negotiation of strategic partnership deals, and the integration of new business acquisitions. Prior to LexisNexis, he served in a range of senior commercial leadership roles at healthcare data and analytics companies, including Health Market Science and IMS Health (now IQVIA). Henderson earned an MBA from Villanova University.

In her new role as COO of Glooko, Stem will have global responsibility for Glooko product development, clinical research, and customer support.

In her previous role, Stem was founder and CEO of monARC Bionetworks, a health data collection and analytics company aimed at modernizing clinical research by empowering patients to share their real-world data generated from routine care and digital tools so it can be transformed into real-world evidence that accelerates research and improves care.

“Glooko’s mission to empower people with diabetes to use their data to improve care and contribute real-world data to advance research is completely aligned with my passion to transform research and care using the growing body of real-world data,” Stem said. “I’m pleased to be joining the Glooko team as we continue leading the way in turning integrated diabetes data into actionable insights for people with diabetes and their providers.”

Prior to monARC Bionetworks, Stem has led the transformation of clinical trials via her leadership roles at Science 37, Genentech, AstraZeneca, Amgen and Eli Lilly. She holds a Master of Science degree in biomedical engineering from the University of Virginia.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts

Robin Beadle
Glooko
[email protected]

Jeff Christensen
SignalWest Public Relations
+1 831-566-0275
[email protected]

Recognition of a Significant Milestone in Larger Data Protection Program of Diabetes Data Management Pioneer
MOUNTAIN VIEW, Calif., Dec. 11, 2019 /PRNewswire/ — Glooko®, the global leader in diabetes data management, today announced it has received Privacy Shield certification from the U.S. Department of Commerce. This official recognition verifies the company has taken specific steps to ensure the protection of consumers’ personal data when transferring it from Europe to the U.S. and has committed to the Privacy Shield Principles, which are intended to protect against the misuse and unwarranted collection of personally-identifying patient information.

In an era of well-publicized consumer data breaches, data privacy and security is a major concern for internet users and has become a growing problem across the board in business. The healthcare industry, in fact, has become particularly susceptible to cyberattacks, and at an average cost of $6.45 million per breach of patient data, health care has the highest average cost per breach of all U.S. business sectors, according to this year’s “Cost of a Data Breach Report” from IBM and the Ponemon Institute. Recent U.S. healthcare data breaches have been attributed to a range of causes, including hacking, IT incidents, and theft, loss, improper disposal, and unauthorized access or disclosure of patient records.

To add to it, the number of breaches in health care continues to increase. After reaching a record high once in 2018 and twice more early this year for the number of data breaches in a single month, U.S. healthcare organizations reached an all-time high yet again in July, reporting a total of 50 data breaches, the most reported in a single month since the HHS Office for Civil Rights established its online database of healthcare breaches in 2010.

That’s why Glooko is especially pleased to have the chance to help lead the way in Privacy Shield certification for diabetes device and data management companies, as only about 10 percent of such companies have pursued and achieved the certification to date.i Even still, the company believes certification must be about more than compliance.

“We’re grateful for Privacy Shield certification and that the mechanism is there to help with compliance. Nevertheless, Glooko has set an internal standard that goes beyond just meeting the minimum requirements regarding data laws,” said Russ Johannesson, CEO of Glooko. “Managing diabetes requires gathering and handling a lot of personal data, and because we believe people with diabetes own their data and protecting their privacy comes first, earning their trust and that of their healthcare providers is our real objective. That far surpasses simply staying inside the lines.”

Privacy Shield was created by the Commerce Department, the European Commission, and the Swiss Administration, and it was activated in 2016. To earn certification, a U.S. company is required to conduct a self-certification process for the Commerce Department and publicly commit to comply with the Privacy Shield Principles. And while Privacy Shield certification is voluntary for U.S. companies, once an eligible company commits to comply with the requirements, the commitment becomes enforceable under U.S. law.

Glooko is proud to have earned the Privacy Shield certification, but it’s a milestone that supports just one part of the larger three-part data protection program that the company is implementing and has made a focus of how it operates. First, Glooko has made a formal declaration of its values regarding data ethics and patient rights via the development and adoption of its Data Ethics Policy, which serves as a guiding light for how the company and its employees will handle health data. It has also gone to great lengths to author and establish its data privacy policies, formalizing them through official certifications like Privacy Shield. And the most rigorous part of Glooko’s program is its actual safeguarding of the data managed on its platform through installing strong security controls, a demanding process being validated by Glooko’s pursuit of the industry-driven seal of approval known as HITRUST Certification.

“As people with diabetes and clinics are managing billions of data points on the Glooko platform, we’re at ‘center stage’ in today’s digital diabetes landscape,” said Melissa Liu, Glooko’s Senior Director of Operations, Privacy & Security. “In light of that pivotal role in handling so much sensitive data, our uncompromising efforts should reassure anyone working with us that Glooko is trustworthy and committed to data protection, from patients and providers to healthcare systems and the device companies with whom we partner.”

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts:

Holly McGarraugh

Glooko

510-282-2852

 

Jeff Christensen

SignalWest Public Relations

+1 831-566-0275

[email protected]

 

Milestone verifies digital health leader’s commitment to ensuring quality and safety of its products

MOUNTAIN VIEW, Calif., Dec. 10, 2019 /PRNewswire/ — Glooko®, the global leader in diabetes data management, announced today that its Mountain View, California and Gothenburg, Sweden sites have received joint ISO 13485:2016 certification from accredited certification body Intertek Testing Services NA Ltd. This certification demonstrates Glooko’s commitment to establishing a compliant quality management system and following practices and procedures that meet customer, safety and regulatory requirements applicable to medical devices. It verifies for regulators, strategic partners, and the diabetes community that Glooko is committed to ensuring the quality and safety of its digital health products and services.

ISO 13485 is an International Organization for Standardization (ISO) standard that describes the requirements for comprehensive practices and procedures for the design, development, production, and delivery of medical devices, including digital health software. To become ISO 13485 certified, Glooko underwent thorough evaluations of its corporate quality management system via a Stage 1 pre-certification audit in June 2019 and Stage 2 certification audits in September 2019 (Mountain View) and October 2019 (Gothenburg), with zero Stage 2 nonconformities noted.

“Organizations in the medical device industry are required to demonstrate their quality management processes and ensure they’re following regulations and standards for developing safe and reliable products,” said Russ Johannesson, CEO of Glooko. “Our certification to ISO 13485 is an important milestone that confirms our quality management system has met internationally-recognized requirements, and that Glooko is committed to ongoing compliance and improvement.”
Because digital health products like Glooko must comply with regulatory standards that meet the quality, safety and clinical needs of people with diabetes and their providers, quality management in digital health is about more than simply developing and testing software.

“Being certified to the ISO 13485 standard is especially important because digital health software is more than a tech product—it is a healthcare product with global quality and safety requirements,” said Mary Beth McDonald, senior director of regulatory and quality management for Glooko.

Beyond regulatory compliance, ISO 13485 certification demonstrates the robustness of Glooko’s quality management system to the Food and Drug Administration (FDA), European Union, and Glooko’s strategic partners.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts:
Holly McGarraugh
Glooko
510-282-2852

Jeff Christensen
SignalWest Public Relations
+1 831-566-0275
[email protected]

New third-party app connections, more compatible devices and in-clinic Bluetooth uploads to better connect patients and their data with clinicians

MOUNTAIN VIEW, California/US and GOTHENBURG, Sweden, 17 September 2019 — Glooko®, the leader in diabetes data management solutions, continues to strengthen its global position with the introduction of several new features and expanded connectivity capabilities for the diasend® by Glooko system at this week’s 55th annual meeting of the European Association for the Study of Diabetes (EASD). The additional device integration partnerships, new ways to upload patient data in clinic, and feature enhancements will be unveiled at the September 17-20 meeting in Barcelona.

Increased device compatibility
At EASD, Europe’s largest and most prominent diabetes meeting, Glooko will share new device integrations it has developed with two new partners:

Additional ways to upload data in-clinic
At the beginning of 2019, NFC connectivity (near-field communication) was introduced in the hardware of the diasend® by Glooko system, which serves as a “one-stop shop” for patients when visiting their health care provider, because it’s able to upload data from numerous devices regardless of brand. Now, BLE (Bluetooth Low Energy) is also added to the mix of ways to upload data to the diasend® solution, providing greater flexibility for the upload process and making clinic/patient interaction even easier. Both NFC and BLE are expected to become increasingly common in diabetes devices during the next couple of years.
“Glooko is pleased to bring additional value to our customers with new data solutions and device integrations on our trusted diasend data management platform,” said Russ Johannesson, CEO of Glooko. “It exemplifies the increasing momentum of Glooko solutions, which provide comprehensive patientbased diabetes data to physicians, better connecting them with their patients. Our greater reach with diasend by Glooko enables healthcare professionals to better focus on value-based outcomes for the patients they serve.”

Prominent speakers at EASD
On the scientific front, Glooko will offer in-booth presentations from two renowned speakers:

“We are proud of the array of diasend by Glooko news that will be showcased at EASD this year, and how it highlights our continuous innovation. We are adding more options to our comprehensive list of compatible devices and introducing new ways for them to function seamlessly with our universal solution,” said Anders Sonesson, Global VP and General Manager of Glooko. “As always, we put our users at the heart of everything we do, and these additions will facilitate the patient/clinic interaction from both sides.”

*Available in selected European countries.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts:
Sebastian Persson
Marketing Director EMEA/APAC
[email protected]
+46 701 46 10 10

Jeff Christensen
SignalWest Public Relations
+1 831-566-0275
[email protected]

Accomplished finance and operations leader brings deep experience in SaaS and healthcare technology to continue acceleration of diabetes data management leader’s growth

MOUNTAIN VIEW, Calif., July 16, 2019—Glooko®, the global leader in diabetes data management solutions, today announced the appointment of Stephen Lien as Chief Financial Officer. Lien comes to Glooko with relevant and extensive experience serving in senior leadership roles in finance and operations across a range of related industries. Some of these include healthcare technology, consumer software, enterprise software, digital media, and software as a service (SaaS). Glooko serves healthcare providers, payers and people with diabetes through its leading FDA-cleared, HIPAA-compliant diabetes management platform.

“We’re very excited to have a seasoned finance and operations executive of Steve’s caliber joining the Glooko team, especially at this stage in our company’s development,” said Russ Johannesson, CEO of Glooko. “Steve is a leader with a strong track record for not only accelerating revenue and maximizing returns but also for scaling global businesses and taking them to the next level, and most recently, that has been with organizations focused on SaaS solutions in the healthcare space.”

Lien comes to Glooko having served most recently as CFO of PipelineRx, a healthcare SaaS technology company that provides pharmacy solutions to inpatient and outpatient pharmacies. Responsible for leading the finance, pharmacy operations, HR and compliance functions at PipelineRx, Lien managed the company’s transformation from a tech-enabled services provider to a technology SaaS subscription company. He also led the company in a Series F Growth Equity round of funding that raised $18 million from strategic investors and $15 million through debt financing, and he was instrumental in growing the company’s recurring annual contract value (ACV) more than 250 percent, year over year.

Prior to PipelineRx, Lien successfully served as CFO at several other companies, including Smart Tuition and SmartCare, a holding company for two SaaS providers (one in the K-12 education space and the other in child care services), where he provided strategic and financial advice leading to the sale of Smart Tuition to Blackbaud for $190 million. Prior to that, as CFO of Skrill Limited—Moneybookers, Inc., a leader in e-commerce and digital payments, Lien built the financial foundation in the U.S. that enabled the sale of the company to CVC Partners for €600 million.

Lien is particularly enthusiastic to be coming to Glooko, where he can continue his work in healthcare technology.

“The global Glooko platform and database have grown into one of the largest in diabetes, serving more than 2.2 million people with diabetes, connecting them with their health care providers and generating powerful insights that are helping guide treatment decisions,” Lien said. “I’m excited to be joining Russ and the rest of the Glooko team in accelerating that growth and scaling the company as we strive to serve more payers, providers, and people with diabetes.”

Lien holds a bachelor’s degree in economics and business administration from the University of California, Berkeley’s Haas School of Business.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 23 countries across 15 languages. Learn more by visiting www.glooko.com.

Media contact:

Holly McGarraugh

Glooko

510-282-2852

 

Jeff Christensen

SignalWest Public Relations

831-566-0275

[email protected]